Co-Morbidity, Body Mass Index and Quality of Life in COPD Using the Clinical COPD Questionnaire

Sundh, Josefin; Ställberg, Björn; Lisspers, Karin; Montgomery, Scott; Janson, Christer

doi:10.3109/15412555.2011.560130

Cited by 55 publications

(70 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2005, the PRAXIS study COPD cohort was created, with primary and secondary care patients from seven county councils in central Sweden [17–20]. Each county council was represented by the department of respiratory medicine in their central hospital, the department of internal medicine from one randomly selected district hospital and eight randomly selected primary health care centers (PHCCs), in a total of 14 hospitals and 56 PHCCs.…”

Section: Methodsmentioning

confidence: 99%

Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014

Sundh

Åberg

Hasselgren

et al. 2017

European Clinical Respiratory Journal

Self Cite

View full text Add to dashboard Cite

Introduction: The aim was to investigate how the pattern of pharmacological treatment in Swedish patients with chronic obstructive pulmonary disease (COPD) has changed over a decade, and to identify factors associated with treatment. Methods: Data on patient characteristics and pharmacological treatment were collected using questionnaires from two separate cohorts of randomly selected primary and secondary care patients with a doctor’s diagnosis of COPD in central Sweden, in 2005 (n = 1111) and 2014 (n = 1329). Cross-tabulations and chi-square tests were used to compare maintenance treatment in 2005 and 2014, and to investigate the distribution of treatment by the 2017 Global Initiative for Obstructive Lung Disease (GOLD) ABCD groups. Multinomial logistic regression was used to analyze associations with the major types of recommended treatments: bronchodilator therapy, combined long-acting beta-2-antagonists (LABA) + inhaled corticosteroids (ICS), and triple inhaled therapy. Results: The proportion of patients with no maintenance treatment, with only LABA + ICS, and with sole ICS statistically significantly decreased (36 vs. 31%, 16 vs. 12% and 5 vs. 2%, respectively), and the proportion with triple inhaled therapy statistically significantly increased (29 vs. 40%). In 2014, triple inhaled therapy was the most common treatment in all GOLD groups except group A. In 2014, previous frequent exacerbations [OR (95% CI) 2.34 (1.62 to 3.36)], worse COPD Assessment Test score [1.07 (1.05 to 1.09)], female sex [2.13 (1.56 to 2.91)], and access to a specific responsible doctor [1.95 (1.41 to 2.69)] were associated with triple inhaled therapy. Current smoking [0.40 (0.28 to 0.57)] and overweight [0.62 (0.41 to 0.93)] were inversely associated with triple inhaled therapy. Conclusions: Over the last decade, triple inhaled therapy has increased, and no maintenance treatment, ICS, or LABA + ICS has decreased. Triple inhaled therapy is the most common treatment and is associated with previous exacerbations, higher symptom level, female sex, and having a specific responsible doctor.

show abstract

Section: Methodsmentioning

confidence: 99%

Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014

Sundh

Åberg

Hasselgren

et al. 2017

European Clinical Respiratory Journal

Self Cite

View full text Add to dashboard Cite

show abstract

“…14,15 A total of 1,548 patients aged 34-75 years with a COPD diagnosis (ICD code J44) recorded in medical records between 2000 and 2003 were randomly selected, 1,084 from primary care and 464 from hospital clinics. …”

Section: Methodsmentioning

confidence: 99%

The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index is predictive of mortality in COPD

Sundh

Janson

Lisspers

et al. 2012

Primary Care Respiratory Journal

Self Cite

View full text Add to dashboard Cite

show abstract

“…Muscle atrophy is often associated with muscle weakness and exercise limitation (545,546), and it worsens the prognosis of many chronic diseases, including COPD (131,547), and impairs health-related quality of life (548,549). Moreover, underweight smokers appear to be more susceptible to develop COPD (550).…”

Section: Nutritional Supplementationmentioning

confidence: 99%

An Official American Thoracic Society/European Respiratory Society Statement: Update on Limb Muscle Dysfunction in Chronic Obstructive Pulmonary Disease

Maltais¹,

Decramer²,

Casaburi³

et al. 2014

Am J Respir Crit Care Med

888

1,033

View full text Add to dashboard Cite

Co-Morbidity, Body Mass Index and Quality of Life in COPD Using the Clinical COPD Questionnaire

Abstract: The CCQ identified that heart disease, depression and underweight are independently associated with lower health-related quality of life in COPD.

Cited by 55 publications

References 47 publications

Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014

Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014

The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index is predictive of mortality in COPD

An Official American Thoracic Society/European Respiratory Society Statement: Update on Limb Muscle Dysfunction in Chronic Obstructive Pulmonary Disease

Contact Info

Product

Resources

About